Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

NCT00962832 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00962832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00962832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
August 31, 2013
Enrollment
238 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus